Published in Immunotherapy Weekly, April 14th, 2004
IMPATH anticipates launching the QCA system in the marketplace early in the second quarter of 2004. Specific terms of the agreement were not disclosed.
Cell Analysis' QCA system has received FDA (U.S. Food and Drug Administration) clearance for estrogen receptor markers in breast cancer and is expected to receive clearance for the oncoprotein, Her2/neu, later in 2004. In addition, the system has been designed to analyze all nuclear,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.